Sojer M, Wissel J, Müller J, Poewe W
Universitätsklinik für Neurologie, Innsbruck, Osterreich.
Wien Klin Wochenschr. 2001;113 Suppl 4:6-10.
Local injections with Botulinum toxin A (BtxA) are safe and effective in the treatment of focal dystonia. In cervical dystonia and blepharospasm, BtxA injections have become the treatment of choice. However, good results have also been reported with oromandibular dystonia, spasmodic dysphonia and writer's cramp. In cervical dystonia, muscles for injection are selected by clinical presentation or in complex forms with EMG guidance. Several studies have shown that 500 units Dysport are safe and effective in the treatment of cervical dystonia. In blepharospasm, injections are performed in the periorbital part of the orbicularis oculi muscle with good results for 12-14 weeks. The most frequently employed starting dose is 120 units Dysport per eye, divided in three periorbital injection sites. In case of levator inhibition, the pretarsal part of the orbicularis oculi muscle should be injected in a lower dose. EMG guidance is not necessary. By contrast, BtxA treatment of spasmodic dysphonia and writer's cramp require EMG-guided injections in order to avoid side-effects. Dose recommendations for the various types of dystonia are given in the text. In up to 5% of patients with dystonia, the development of neutralising antibodies is reported following repetitive injections with BtxA. Patients with antibodies had a shorter interval between injections, more "boosters", a higher dose per 3-month interval, and a higher total dose injected. In case of neutralizing antibodies against the A toxin, the treatment with Botulinum toxin B (Neurobloc) is a possible alternative.
局部注射A型肉毒杆菌毒素(BtxA)治疗局灶性肌张力障碍安全有效。在颈部肌张力障碍和眼睑痉挛的治疗中,BtxA注射已成为首选治疗方法。然而,口下颌肌张力障碍、痉挛性发音困难和书写痉挛的治疗也有良好效果的报道。在颈部肌张力障碍中,根据临床表现或在肌电图引导下以复杂形式选择注射肌肉。多项研究表明,500单位的Dysport治疗颈部肌张力障碍安全有效。在眼睑痉挛中,在眼轮匝肌眶周部分进行注射,12 - 14周效果良好。最常用的起始剂量是每只眼120单位Dysport,分三个眶周注射部位注射。如果出现提上睑肌抑制,应降低剂量注射眼轮匝肌睑板前部分。无需肌电图引导。相比之下,BtxA治疗痉挛性发音困难和书写痉挛需要肌电图引导注射以避免副作用。文中给出了各种类型肌张力障碍的剂量建议。在高达5%的肌张力障碍患者中,重复注射BtxA后会出现中和抗体。有抗体的患者注射间隔时间更短、“加强针”更多(此处原文“boosters”可能有误,推测为“booster injections”即加强针)、每3个月间隔剂量更高以及总注射剂量更高。如果出现针对A毒素的中和抗体,可用B型肉毒杆菌毒素(Neurobloc)进行替代治疗。